Illumina (ILMN)
(Delayed Data from NSDQ)
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 5:04 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.49 USD
+3.73 (2.49%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $150.00 -3.49 (-2.27%) 5:04 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable
by Zacks Equity Research
Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.
Illumina (ILMN) NGS-Based Platform Approved for Use in Russia
by Zacks Equity Research
Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $398.85, moving -0.19% from the previous trading session.
Myriad Genetics (MYGN) Collaborates to Advance Oncology Care
by Zacks Equity Research
Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
by Zacks Equity Research
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
Myriad Genetics' (MYGN) Prolaris Test Study Outcome Favorable
by Zacks Equity Research
Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.
Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.
Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 0.83% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
New Study Favors Myriad Genetics' (MYGN) GeneSight Test
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.
Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.
Illumina (ILMN) New Collaboration to Aid Genomics Startups
by Zacks Equity Research
Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.
Baidu, Illumina, American Axle & Manufacturing, International Paper and KB Home highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Baidu, Illumina, American Axle & Manufacturing, International Paper and KB Home highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
Illumina (ILMN) is in Overbought Territory: What's Next?
by Zacks Equity Research
Illumina (ILMN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
New Strong Sell Stocks for January 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Myriad Genetics (MYGN), Illumina Partner to Enhance Oncology Arm
by Zacks Equity Research
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.
by Zacks Equity Research
Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access
by Zacks Equity Research
Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.
Scottish Warlords of Investing: Baillie Gifford Sells TSLA, Buys TTD, Holds SHOP
by Kevin Cook
They didn't want to sell Tesla ever, but their profits were just to enormous.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and worldwide expansion to drive growth.
Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.
Illumina (ILMN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 32.47% and 10.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: StoneCo, Las Vegas Sands, Yandex and Illumina
by Zacks Equity Research
Zacks.com featured highlights include: StoneCo, Las Vegas Sands, Yandex and Illumina